Abbott: Michael F. Roman acquires 381 share-linked units
The stock equivalent units are paid in cash generally at age 65 or upon retirement from the board.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Abbott Laboratories director Michael F. Roman acquired 381 stock equivalent units on September 30, 2026, at a reported $98.83 per unit. His reported balance after the acquisition was 7,166 stock equivalent units, including units acquired through a dividend reinvestment feature. Director fees are credited to the account, which earns the same return as if the fees were invested in Abbott shares; the units are paid in cash generally at age 65 or upon retirement from the board.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Equivalent Units F1, F2 | 381 | $98.83 | $38K |
Footnotes (2)
- F1. Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.
- F2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
Key Figures
Key Terms
stock equivalent unit account financial
dividend reinvestment feature financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many ABT stock equivalent units did Michael F. Roman acquire?
How do ABT stock equivalent units work?
AI-generated analysis. How Rhea-AI works. Not financial advice.